<DOC>
	<DOCNO>NCT02245412</DOCNO>
	<brief_summary>The objective trial evaluate safety , tolerability , pharmacokinetics/pharmacodynamics ( PK/PD ) efficacy intravenous ( IV ) ALXN1007 subject acute graft-versus-host disease ( GVHD ) low gastrointestinal ( GI ) tract .</brief_summary>
	<brief_title>A Phase 2a Study ALXN1007 Subjects With Newly Diagnosed Acute GI GVHD</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Subjects must males female age 18 year old . Subjects Stage 14 ( per Modified Keystone Grading Schema ) acute GVHD low GI tract , without sign chronic GVHD , time diagnosis , develop first 180 day follow allogeneic hematopoietic cell transplantation ( HCT ) use bone marrow , peripheral blood , cord blood ; preplanned donor lymphocyte infusion . Subjects willing undergo must endoscopy upper and/or lower GI tract biopsy confirm GI GVHD . Subjects must receive systemic corticosteroid . Subjects absolute neutrophil count ( ANC ) &gt; 500/Î¼L Screening . Subjects spouse/partner childbearing potential must use high effective contraception consist 2 form birth control ( least 1 much barrier method ) start Screening continue entire study ( least 3 month last dose ALXN1007 study treatment stop early subject withdraws consent ) . Male subject must donate sperm Screening Treatment period , least 3 month last dose ALXN1007 . Stage acute GVHD low GI tract determine use Modified Keystone Grading Schema . Subjects body weight &gt; 140 kg ( Cohorts dose 20 mg/kg ALXN1007 high ) . Subjects sign symptom chronic GVHD . Subjects active uncontrolled infection . Subjects test positive Clostridium difficile ( C. difficile ) Screening . Subjects relapsed/persistent malignancy require rapid immune suppression withdrawal . Subjects receive unplanned ( part original transplant therapy plan ) donor lymphocyte infusion . Subjects receive previous systemic treatment acute GVHD , except maximum 3 day ( 72 hour ) 2 mg/kg corticosteroid therapy . Subjects unresolved venoocclusive disease liver . Subjects creatinine clearance &lt; 40 mL/minute Screening , calculate CockroftGault formula . Subjects know infectged human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C. Subjects know uncontrolled thyroid disorder . Subjects pregnant , breast feeding sexually active unwilling use effective birth control duration study . Subjects participate investigational drug trial exposure investigational agent , device procedure &lt; 4 week prior Screening throughout entire trial , exception investigational drug administer prophylactically CMV post allogeneic HCT .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>